Search results
Showing 3001 to 3050 of 4091 results for patient
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Awaiting development Reference number: GID-TA11784 Expected publication date: 21 July 2027
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
In development Reference number: GID-TA11425 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11494 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC
Awaiting development Reference number: GID-TA11490 Expected publication date: TBC
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
Awaiting development Reference number: GID-TA11840 Expected publication date: TBC
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
BRAHMS copeptin assay to rule out myocardial infarction in patients with acute chest pain (MTG4)
In November 2016, NICE reviewed this guidance and recommended that it should be withdrawn. The guidance was published in June 2011 and recommended that further research was carried out on the technology. There was insufficient evidence on its use in clinical practice to recommend adoption. On reviewing the guidance in 2016, NICE determined that: The comparator in the original guidance, standard serial troponin testing, was changed in 2014 to high sensitivity troponin testing which expert advice indicated is now widespread in the NHS The clinical pathway in the original evaluation has significantly changed and the original scope is no longer valid. These changes mean that the current guidance is no longer valid and NICE would not be able to update it. The guidance has therefore been withdrawn. For a copy of the review decision please contact nice@nice.org.uk.
This guidance has been updated and replaced by NICE guideline NG107
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
Developmental follow-up of children and young people born preterm (NG72)
This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
In development Reference number: GID-TA11085 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
In development Reference number: GID-TA11862 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture [ID6276]
Awaiting development Reference number: GID-TA11363 Expected publication date: TBC
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
In development Reference number: GID-TA11718 Expected publication date: TBC
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
Evidence-based recommendations on percutaneous venoplasty for chronic cerebrospinal venous insufficiency in people with multiple sclerosis. This involves inserting an inflatable balloon into veins in the neck and chest in an attempt to widen them.
View recommendations for HTG501Show all sections
Bipolar, schizophrenia and other psychoses: cervical screening (IND85)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20
This indicator covers the contractor establishing and maintaining a register of patients with atrial fibrillation, including patients with ‘AF resolved’. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM164
In development Reference number: GID-TA10998 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
In development Reference number: GID-TA11699 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
In development Reference number: GID-TA11615 Expected publication date: TBC
In development Reference number: GID-TA11583 Expected publication date: TBC
In development Reference number: GID-TA11866 Expected publication date: TBC
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Awaiting development Reference number: GID-TA11868 Expected publication date: TBC
In development Reference number: GID-TA11801 Expected publication date: TBC
In development Reference number: GID-TA11836 Expected publication date: TBC
Awaiting development Reference number: GID-TA11872 Expected publication date: TBC
Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]
In development Reference number: GID-TA11818 Expected publication date: TBC